Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant
Gespeichert in:
| Veröffentlicht in: | Cell research 2022-04, Vol.32 (4), p.404-406 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 406 |
|---|---|
| container_issue | 4 |
| container_start_page | 404 |
| container_title | Cell research |
| container_volume | 32 |
| creator | Xia, Shuai Chan, Jasper Fuk-Woo Wang, Lijue Jiao, Fanke Chik, Kenn Ka-Heng Chu, Hin Lan, Qiaoshuai Xu, Wei Wang, Qian Wang, Chao Yuen, Kwok-Yung Lu, Lu Jiang, Shibo |
| description | |
| doi_str_mv | 10.1038/s41422-022-00617-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8793821</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2646021505</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-8df85541965639e06ec7bbd0e3e4855d53755544b2c322c8e47af3e44af2dd303</originalsourceid><addsrcrecordid>eNp9UUtPGzEQtlARUOgf4IAs9ewyfq2dCxKK6ENCApXH1fXuehMj4l1sByX_Hq8SQnvpYWRrvseM_SF0SuEbBa7Pk6CCMQJjQUUVWe2hI6qEJkpz_ancASiBCtgh-pzSEwCTQtIDdMglaMUEP0J_bt2QfetIbZNr8WADmfaPuFsm3wfsw9zXPvcx4YX1IZfCcz-b46HPLjRrbGellTK-u_x9NwoJwzcL38SifbXR25BP0H5nn5P7sj2P0cP3q_vpT3J98-PX9PKaNEKJTHTbaSkFnVSy4hMHlWtUXbfguBMFaCVXsuCiZg1nrNFOKNsVTNiOtS0HfowuNr7Dsl64tnEhR_tshugXNq5Nb735Fwl-bmb9q9FqwjWjxeDr1iD2L0uXsnnqlzGUnQ2rRPlEKkEWFtuwyhtTiq7bTaBgxlTMJhUDY42pmFURnf29207yHkMh8A0hFSjMXPyY_R_bN1OumRk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2646021505</pqid></control><display><type>article</type><title>Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant</title><source>PubMed (Medline)</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Xia, Shuai ; Chan, Jasper Fuk-Woo ; Wang, Lijue ; Jiao, Fanke ; Chik, Kenn Ka-Heng ; Chu, Hin ; Lan, Qiaoshuai ; Xu, Wei ; Wang, Qian ; Wang, Chao ; Yuen, Kwok-Yung ; Lu, Lu ; Jiang, Shibo</creator><creatorcontrib>Xia, Shuai ; Chan, Jasper Fuk-Woo ; Wang, Lijue ; Jiao, Fanke ; Chik, Kenn Ka-Heng ; Chu, Hin ; Lan, Qiaoshuai ; Xu, Wei ; Wang, Qian ; Wang, Chao ; Yuen, Kwok-Yung ; Lu, Lu ; Jiang, Shibo</creatorcontrib><identifier>ISSN: 1001-0602</identifier><identifier>EISSN: 1748-7838</identifier><identifier>DOI: 10.1038/s41422-022-00617-x</identifier><identifier>PMID: 35087243</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>631/337 ; 631/80 ; Biomedical and Life Sciences ; Cell Biology ; COVID-19 - drug therapy ; Humans ; Letter to the Editor ; Life Sciences ; Mutation ; Peptides ; Peptides - pharmacology ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2</subject><ispartof>Cell research, 2022-04, Vol.32 (4), p.404-406</ispartof><rights>The Author(s) under exclusive licence to Center for Excellence in Molecular Cell Science, CAS 2022</rights><rights>The Author(s) under exclusive licence to Center for Excellence in Molecular Cell Science, CAS 2022.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-8df85541965639e06ec7bbd0e3e4855d53755544b2c322c8e47af3e44af2dd303</citedby><cites>FETCH-LOGICAL-c474t-8df85541965639e06ec7bbd0e3e4855d53755544b2c322c8e47af3e44af2dd303</cites><orcidid>0000-0001-8283-7135 ; 0000-0003-2855-9837 ; 0000-0002-2255-0391 ; 0000-0002-2083-1552 ; 0000-0001-5524-3542</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793821/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793821/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35087243$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xia, Shuai</creatorcontrib><creatorcontrib>Chan, Jasper Fuk-Woo</creatorcontrib><creatorcontrib>Wang, Lijue</creatorcontrib><creatorcontrib>Jiao, Fanke</creatorcontrib><creatorcontrib>Chik, Kenn Ka-Heng</creatorcontrib><creatorcontrib>Chu, Hin</creatorcontrib><creatorcontrib>Lan, Qiaoshuai</creatorcontrib><creatorcontrib>Xu, Wei</creatorcontrib><creatorcontrib>Wang, Qian</creatorcontrib><creatorcontrib>Wang, Chao</creatorcontrib><creatorcontrib>Yuen, Kwok-Yung</creatorcontrib><creatorcontrib>Lu, Lu</creatorcontrib><creatorcontrib>Jiang, Shibo</creatorcontrib><title>Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant</title><title>Cell research</title><addtitle>Cell Res</addtitle><addtitle>Cell Res</addtitle><subject>631/337</subject><subject>631/80</subject><subject>Biomedical and Life Sciences</subject><subject>Cell Biology</subject><subject>COVID-19 - drug therapy</subject><subject>Humans</subject><subject>Letter to the Editor</subject><subject>Life Sciences</subject><subject>Mutation</subject><subject>Peptides</subject><subject>Peptides - pharmacology</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><issn>1001-0602</issn><issn>1748-7838</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9UUtPGzEQtlARUOgf4IAs9ewyfq2dCxKK6ENCApXH1fXuehMj4l1sByX_Hq8SQnvpYWRrvseM_SF0SuEbBa7Pk6CCMQJjQUUVWe2hI6qEJkpz_ancASiBCtgh-pzSEwCTQtIDdMglaMUEP0J_bt2QfetIbZNr8WADmfaPuFsm3wfsw9zXPvcx4YX1IZfCcz-b46HPLjRrbGellTK-u_x9NwoJwzcL38SifbXR25BP0H5nn5P7sj2P0cP3q_vpT3J98-PX9PKaNEKJTHTbaSkFnVSy4hMHlWtUXbfguBMFaCVXsuCiZg1nrNFOKNsVTNiOtS0HfowuNr7Dsl64tnEhR_tshugXNq5Nb735Fwl-bmb9q9FqwjWjxeDr1iD2L0uXsnnqlzGUnQ2rRPlEKkEWFtuwyhtTiq7bTaBgxlTMJhUDY42pmFURnf29207yHkMh8A0hFSjMXPyY_R_bN1OumRk</recordid><startdate>20220401</startdate><enddate>20220401</enddate><creator>Xia, Shuai</creator><creator>Chan, Jasper Fuk-Woo</creator><creator>Wang, Lijue</creator><creator>Jiao, Fanke</creator><creator>Chik, Kenn Ka-Heng</creator><creator>Chu, Hin</creator><creator>Lan, Qiaoshuai</creator><creator>Xu, Wei</creator><creator>Wang, Qian</creator><creator>Wang, Chao</creator><creator>Yuen, Kwok-Yung</creator><creator>Lu, Lu</creator><creator>Jiang, Shibo</creator><general>Springer Singapore</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8283-7135</orcidid><orcidid>https://orcid.org/0000-0003-2855-9837</orcidid><orcidid>https://orcid.org/0000-0002-2255-0391</orcidid><orcidid>https://orcid.org/0000-0002-2083-1552</orcidid><orcidid>https://orcid.org/0000-0001-5524-3542</orcidid></search><sort><creationdate>20220401</creationdate><title>Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant</title><author>Xia, Shuai ; Chan, Jasper Fuk-Woo ; Wang, Lijue ; Jiao, Fanke ; Chik, Kenn Ka-Heng ; Chu, Hin ; Lan, Qiaoshuai ; Xu, Wei ; Wang, Qian ; Wang, Chao ; Yuen, Kwok-Yung ; Lu, Lu ; Jiang, Shibo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-8df85541965639e06ec7bbd0e3e4855d53755544b2c322c8e47af3e44af2dd303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>631/337</topic><topic>631/80</topic><topic>Biomedical and Life Sciences</topic><topic>Cell Biology</topic><topic>COVID-19 - drug therapy</topic><topic>Humans</topic><topic>Letter to the Editor</topic><topic>Life Sciences</topic><topic>Mutation</topic><topic>Peptides</topic><topic>Peptides - pharmacology</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xia, Shuai</creatorcontrib><creatorcontrib>Chan, Jasper Fuk-Woo</creatorcontrib><creatorcontrib>Wang, Lijue</creatorcontrib><creatorcontrib>Jiao, Fanke</creatorcontrib><creatorcontrib>Chik, Kenn Ka-Heng</creatorcontrib><creatorcontrib>Chu, Hin</creatorcontrib><creatorcontrib>Lan, Qiaoshuai</creatorcontrib><creatorcontrib>Xu, Wei</creatorcontrib><creatorcontrib>Wang, Qian</creatorcontrib><creatorcontrib>Wang, Chao</creatorcontrib><creatorcontrib>Yuen, Kwok-Yung</creatorcontrib><creatorcontrib>Lu, Lu</creatorcontrib><creatorcontrib>Jiang, Shibo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest - Health & Medical Complete保健、医学与药学数据库</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cell research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xia, Shuai</au><au>Chan, Jasper Fuk-Woo</au><au>Wang, Lijue</au><au>Jiao, Fanke</au><au>Chik, Kenn Ka-Heng</au><au>Chu, Hin</au><au>Lan, Qiaoshuai</au><au>Xu, Wei</au><au>Wang, Qian</au><au>Wang, Chao</au><au>Yuen, Kwok-Yung</au><au>Lu, Lu</au><au>Jiang, Shibo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant</atitle><jtitle>Cell research</jtitle><stitle>Cell Res</stitle><addtitle>Cell Res</addtitle><date>2022-04-01</date><risdate>2022</risdate><volume>32</volume><issue>4</issue><spage>404</spage><epage>406</epage><pages>404-406</pages><issn>1001-0602</issn><eissn>1748-7838</eissn><cop>Singapore</cop><pub>Springer Singapore</pub><pmid>35087243</pmid><doi>10.1038/s41422-022-00617-x</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0001-8283-7135</orcidid><orcidid>https://orcid.org/0000-0003-2855-9837</orcidid><orcidid>https://orcid.org/0000-0002-2255-0391</orcidid><orcidid>https://orcid.org/0000-0002-2083-1552</orcidid><orcidid>https://orcid.org/0000-0001-5524-3542</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1001-0602 |
| ispartof | Cell research, 2022-04, Vol.32 (4), p.404-406 |
| issn | 1001-0602 1748-7838 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8793821 |
| source | PubMed (Medline); MEDLINE; Alma/SFX Local Collection; EZB Electronic Journals Library |
| subjects | 631/337 631/80 Biomedical and Life Sciences Cell Biology COVID-19 - drug therapy Humans Letter to the Editor Life Sciences Mutation Peptides Peptides - pharmacology SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 |
| title | Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T15%3A20%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Peptide-based%20pan-CoV%20fusion%20inhibitors%20maintain%20high%20potency%20against%20SARS-CoV-2%20Omicron%20variant&rft.jtitle=Cell%20research&rft.au=Xia,%20Shuai&rft.date=2022-04-01&rft.volume=32&rft.issue=4&rft.spage=404&rft.epage=406&rft.pages=404-406&rft.issn=1001-0602&rft.eissn=1748-7838&rft_id=info:doi/10.1038/s41422-022-00617-x&rft_dat=%3Cproquest_pubme%3E2646021505%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2646021505&rft_id=info:pmid/35087243&rfr_iscdi=true |